MedTrace Logo

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

NCT06912295 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-08-24

No results posted yet for this study

Summary

This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration.

Sponsors & Collaborators

  • Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-21
Primary Completion
2025-08-30
Completion
2025-10-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06912295 on ClinicalTrials.gov